Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor-Pretreated Fusion-Positive Intrahepatic Cholangiocarcinoma: Case Report.
d'Arienzo, Paolo D MacDonald, Alan R Patel, Virjen Ma, Yuk T Pihlak, Rille Starling, Naureen
d'Arienzo, Paolo D
MacDonald, Alan R
Patel, Virjen
Ma, Yuk T
Pihlak, Rille
Starling, Naureen
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2024-06-13
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Multiple FGFR inhibitors have demonstrated significant activity in pretreated advanced FGFR2 fusion-positive intrahepatic cholangiocarcinoma. The irreversible pan-FGFR inhibitor futibatinib has the potential to overcome acquired resistance to ATP-competitive FGFR inhibitors in a subset of patients. We present a case of prolonged clinical benefit using FGFR inhibitors sequentially, initially an ATP-competitive inhibitor followed by futibatinib upon progression, for a total of 36 months of FGFR-targeting therapy. This case supports sequential FGFR-targeting therapies for FGFR2 fusion-positive cholangiocarcinoma, with futibatinib acting as rescue therapy after failure of ATP-competitive inhibitors.
Citation
d'Arienzo PD, MacDonald AR, Patel V, Ma YT, Pihlak R, Starling N. Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor-Pretreated FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma: Case Report. Onco Targets Ther. 2024 Jun 13;17:489-496. doi: 10.2147/OTT.S434449.
Type
Article
Other
Other